Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

15.22
+0.47003.19%
Post-market: 15.05-0.1700-1.12%19:54 EDT
Volume:3.88M
Turnover:58.72M
Market Cap:1.50B
PE:-2.61
High:15.28
Open:14.90
Low:14.67
Close:14.75
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.82
T/O Rate:4.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-5.14
PE(LYR):-2.61

Loading ...

Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating

MT Newswires Live
·
Jul 13

Ultragenyx Releases 2025 Impact Report Outlining ESG Progress Across Six Pillars

Reuters
·
Jul 08

RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating

MT Newswires Live
·
Jul 07

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors

THOMSON REUTERS
·
Jun 23

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire
·
Jun 23

Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs

Reuters
·
Jun 22

Ultragenyx grants 44,409 RSUs to 15 new hires under inducement plan

Reuters
·
Jun 20

Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Jun 20

Ultragenyx (RARE) Is Up 17.6% After ESOP Share Shelf And Conference Spotlight On Gene Therapies – Has The Bull Case Changed?

Simply Wall St.
·
Jun 17

Ultragenyx EVP, Chief Legal Officer Karah Parschauer reports sale of 1,899 common shares worth $46,749.38

Reuters
·
Jun 16

Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism

Simply Wall St.
·
Jun 09

Does Rising GTX-102 Focus Recast Ultragenyx (RARE) as a Concentrated Angelman Syndrome Risk-Reward Story?

Simply Wall St.
·
Jun 07

Ultragenyx Pharmaceutical (RARE) Receives a Buy from J.P. Morgan

TIPRANKS
·
May 23

Ultragenyx grants 17,567 RSUs to 11 new hires under inducement plan

Reuters
·
May 23

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 23

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 23

Ultragenyx Pharma Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
May 21

Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald

TIPRANKS
·
May 21

Ultragenyx director Shehnaaz Suliman disposes 5,740 common shares for $144,228.8

Reuters
·
May 19

Ultragenyx shareholders approve amended 2023 incentive plan at annual meeting

Reuters
·
May 19